Src as a potential therapeutic target in non-small-cell lung cancerGIACCONE, G; ZUCALI, P. A.Annals of oncology. 2008, Vol 19, Num 7, pp 1219-1223, issn 0923-7534, 5 p.Article

2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trialBACHNER, M; LORIOT, Y; GILLESSEN, S et al.Annals of oncology. 2012, Vol 23, Num 1, pp 59-64, issn 0923-7534, 6 p.Article

New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesotheliomaZUCALI, P. A; GIOVANNETTI, E; ASSARAF, Y. G et al.Annals of oncology. 2010, Vol 21, Num 7, pp 1560-1561, issn 0923-7534, 2 p.Article

Irinotecan and raltitrexed: an active combination in advanced colorectal cancerCARNAGHI, C; RIMASSA, L; GARASSINO, I et al.Annals of oncology. 2002, Vol 13, Num 9, pp 1424-1429, issn 0923-7534, 6 p.Article

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesotheliomaCERESOLI, G. L; ZUCALI, P. A; SOTO-PARRA, H et al.British journal of cancer. 2013, Vol 109, Num 3, pp 552-558, issn 0007-0920, 7 p.Article

Reproducibility of the WHO classification of thymomas: Practical implicationsZUCALI, P. A; DI TOMMASO, L; RONCALLI, M et al.Lung cancer. 2013, Vol 79, Num 3, pp 236-241, issn 0169-5002, 6 p.Article

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma : combined analysis of two phase II trialsCERESOLI, G. L; CASTAGNETO, B; SALAMINA, S et al.British journal of cancer. 2008, Vol 99, Num 1, pp 51-56, issn 0007-0920, 6 p.Article

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter surveyCERESOLI, G. L; GROSSO, F; PICCOLINI, E et al.British journal of cancer. 2014, Vol 111, Num 2, pp 220-226, issn 0007-0920, 7 p.Article

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsCAPPUZZO, F; JÄNNE, P. A; DESTRO, A et al.Annals of oncology. 2009, Vol 20, Num 2, pp 298-304, issn 0923-7534, 7 p.Article

Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancerSANTORO, A; CAVINA, R; ALLOISIO, M et al.Annals of oncology. 2004, Vol 15, Num 1, pp 33-37, issn 0923-7534, 5 p.Article

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesotheliomaZUCALI, P. A; PERRINO, M; LORENZI, E et al.Lung cancer. 2014, Vol 84, Num 3, pp 265-270, issn 0169-5002, 6 p.Article

Phase I and pharmacodynamic study of high-dose NGR―hTNF in patients with refractory solid tumoursZUCALI, P. A; SIMONELLI, M; TIMOFEEVA, I et al.British journal of cancer. 2013, Vol 108, Num 1, pp 58-63, issn 0007-0920, 6 p.Article

Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter surveyZUCALI, P. A; SIMONELLI, M; LORENZI, E et al.Lung cancer. 2012, Vol 75, Num 3, pp 360-367, issn 0169-5002, 8 p.Article

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatinGIOVANNETTI, E; ZUCALI, P. A; RONCALLI, M et al.British journal of cancer. 2011, Vol 105, Num 10, pp 1542-1553, issn 0007-0920, 12 p.Article

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitorsZUCALI, P. A; RUIZ, M. G; RONCALLI, M et al.Annals of oncology. 2008, Vol 19, Num 9, pp 1605-1612, issn 0923-7534, 8 p.Article

EGFR overexpression in malignant pleural mesothelioma an immunohistochemical and molecular study with clinico-pathological correlationsDESTRO, A; CERESOLI, G. L; RIZZI, A et al.Lung cancer. 2006, Vol 51, Num 2, pp 207-215, issn 0169-5002, 9 p.Article

Malignant pleural mesotheliomaCERESOLI, G. L; BETTA, G. P; CASTAGNETO, B et al.Annals of oncology. 2006, Vol 17, issn 0923-7534, ii13-ii16, SUP2Conference Paper

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZDI839) in non-small-cell lung cancerPARRA, H. S; CAVINA, R; LATTERI, F et al.British journal of cancer. 2004, Vol 91, Num 2, pp 208-212, issn 0007-0920, 5 p.Article